·10 min readFeatured
Biotech Intelligence #12: What the GSK-Hengrui Deal Really Says About China Licensing
GSK-Hengrui's roughly $12B multi-asset deal suggests Western pharma is getting more comfortable underwriting Chinese platform depth. Also this week: BIOSECURE timing, CDE signals, and what WuXi exposure really means.
GSKHengruiADCBIOSECUREdeal-analysis